Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Macrophages | 17 | 2011 | 571 | 1.830 |
Why?
|
Cord Blood Stem Cell Transplantation | 9 | 2017 | 89 | 1.550 |
Why?
|
Leukemia, Myeloid, Acute | 7 | 2018 | 779 | 1.340 |
Why?
|
Arthritis, Rheumatoid | 11 | 2006 | 167 | 1.330 |
Why?
|
Transplantation Conditioning | 12 | 2018 | 372 | 1.130 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 6 | 2006 | 192 | 0.970 |
Why?
|
Hematopoietic Stem Cell Transplantation | 10 | 2018 | 883 | 0.870 |
Why?
|
Apoptosis | 13 | 2006 | 1705 | 0.830 |
Why?
|
Neoplasm Proteins | 5 | 2006 | 539 | 0.760 |
Why?
|
Synovial Membrane | 8 | 2006 | 28 | 0.740 |
Why?
|
Enbucrilate | 2 | 2011 | 7 | 0.700 |
Why?
|
Graft vs Host Disease | 8 | 2017 | 357 | 0.680 |
Why?
|
Monocytes | 7 | 2011 | 217 | 0.680 |
Why?
|
Mitoxantrone | 1 | 2018 | 68 | 0.610 |
Why?
|
Cytarabine | 1 | 2018 | 219 | 0.590 |
Why?
|
NF-kappa B | 8 | 2005 | 459 | 0.580 |
Why?
|
Neoplasm, Residual | 2 | 2015 | 172 | 0.570 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2011 | 237 | 0.560 |
Why?
|
Tumor Necrosis Factor-alpha | 9 | 2006 | 695 | 0.560 |
Why?
|
Embolization, Therapeutic | 2 | 2011 | 251 | 0.550 |
Why?
|
Hematologic Neoplasms | 3 | 2016 | 335 | 0.510 |
Why?
|
Proto-Oncogene Proteins | 3 | 2003 | 655 | 0.490 |
Why?
|
Pharyngectomy | 1 | 2013 | 8 | 0.470 |
Why?
|
Lasers, Solid-State | 1 | 2013 | 8 | 0.470 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2013 | 47 | 0.450 |
Why?
|
Graft Survival | 4 | 2016 | 905 | 0.450 |
Why?
|
Antineoplastic Agents | 2 | 2018 | 2392 | 0.440 |
Why?
|
Cerebral Angiography | 2 | 2010 | 197 | 0.420 |
Why?
|
Stem Cell Transplantation | 2 | 2013 | 187 | 0.420 |
Why?
|
Transplantation, Homologous | 11 | 2018 | 1000 | 0.420 |
Why?
|
Cell Survival | 6 | 2011 | 977 | 0.420 |
Why?
|
Gene Expression Regulation | 7 | 2008 | 1956 | 0.400 |
Why?
|
Dextrans | 1 | 2011 | 77 | 0.400 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2011 | 37 | 0.390 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2011 | 64 | 0.390 |
Why?
|
Biliopancreatic Diversion | 1 | 2010 | 4 | 0.380 |
Why?
|
Induction Chemotherapy | 1 | 2011 | 149 | 0.380 |
Why?
|
Aged | 21 | 2018 | 18750 | 0.370 |
Why?
|
Fibroblasts | 6 | 2005 | 736 | 0.370 |
Why?
|
Intestinal Absorption | 1 | 2010 | 124 | 0.370 |
Why?
|
DNA-Binding Proteins | 6 | 2003 | 1224 | 0.360 |
Why?
|
Humans | 50 | 2018 | 87949 | 0.360 |
Why?
|
Middle Aged | 22 | 2018 | 25477 | 0.350 |
Why?
|
Subtraction Technique | 1 | 2010 | 132 | 0.350 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 2516 | 0.340 |
Why?
|
Gastric Bypass | 1 | 2010 | 110 | 0.340 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2010 | 172 | 0.340 |
Why?
|
Vertebral Artery Dissection | 1 | 2009 | 11 | 0.330 |
Why?
|
Remission Induction | 3 | 2018 | 734 | 0.330 |
Why?
|
Carotid Artery, Internal, Dissection | 1 | 2009 | 20 | 0.330 |
Why?
|
Piperazines | 1 | 2010 | 278 | 0.330 |
Why?
|
Brain Infarction | 1 | 2009 | 22 | 0.330 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2013 | 1347 | 0.310 |
Why?
|
Subarachnoid Hemorrhage | 1 | 2009 | 137 | 0.310 |
Why?
|
Pyrimidines | 1 | 2010 | 370 | 0.310 |
Why?
|
Myelodysplastic Syndromes | 3 | 2017 | 351 | 0.310 |
Why?
|
Hemodynamics | 1 | 2011 | 723 | 0.310 |
Why?
|
Fetal Blood | 4 | 2017 | 90 | 0.300 |
Why?
|
Haplotypes | 3 | 2016 | 637 | 0.290 |
Why?
|
Tissue Adhesives | 1 | 2007 | 23 | 0.290 |
Why?
|
Synovial Fluid | 2 | 2005 | 10 | 0.290 |
Why?
|
Adult | 17 | 2018 | 26131 | 0.280 |
Why?
|
Recurrence | 5 | 2017 | 1168 | 0.280 |
Why?
|
Mitochondria | 5 | 2006 | 545 | 0.280 |
Why?
|
Immunotherapy | 1 | 2011 | 655 | 0.270 |
Why?
|
Chimerism | 3 | 2016 | 36 | 0.270 |
Why?
|
Treatment Outcome | 10 | 2018 | 8104 | 0.260 |
Why?
|
Intracellular Membranes | 3 | 2006 | 117 | 0.260 |
Why?
|
Survival Analysis | 6 | 2017 | 1539 | 0.260 |
Why?
|
Myeloid Cell Leukemia Sequence 1 Protein | 4 | 2006 | 35 | 0.240 |
Why?
|
Female | 22 | 2018 | 45399 | 0.240 |
Why?
|
Phagocytes | 1 | 2004 | 10 | 0.240 |
Why?
|
Synovitis | 1 | 2004 | 14 | 0.240 |
Why?
|
Transcription, Genetic | 3 | 2008 | 1144 | 0.240 |
Why?
|
Brain Ischemia | 1 | 2009 | 402 | 0.240 |
Why?
|
Granulomatosis with Polyangiitis | 1 | 2004 | 9 | 0.240 |
Why?
|
Vasculitis | 1 | 2004 | 39 | 0.230 |
Why?
|
Magnetic Resonance Imaging | 2 | 2013 | 3425 | 0.230 |
Why?
|
Proto-Oncogene Proteins c-jun | 2 | 2000 | 33 | 0.230 |
Why?
|
Male | 19 | 2018 | 41697 | 0.230 |
Why?
|
Geriatric Assessment | 2 | 2015 | 181 | 0.230 |
Why?
|
Trans-Activators | 2 | 2003 | 436 | 0.230 |
Why?
|
Tomography, X-Ray Computed | 2 | 2011 | 2624 | 0.220 |
Why?
|
Caspases | 7 | 2005 | 155 | 0.220 |
Why?
|
Combined Modality Therapy | 3 | 2017 | 1703 | 0.210 |
Why?
|
Phosphatidylinositol 3-Kinases | 4 | 2006 | 266 | 0.210 |
Why?
|
Retrospective Studies | 7 | 2017 | 8780 | 0.200 |
Why?
|
Intracellular Signaling Peptides and Proteins | 4 | 2004 | 383 | 0.190 |
Why?
|
Membrane Glycoproteins | 4 | 2004 | 430 | 0.190 |
Why?
|
Carrier Proteins | 6 | 2004 | 677 | 0.180 |
Why?
|
STAT3 Transcription Factor | 3 | 2006 | 81 | 0.180 |
Why?
|
Aged, 80 and over | 6 | 2018 | 6655 | 0.170 |
Why?
|
Young Adult | 9 | 2017 | 6151 | 0.170 |
Why?
|
Unrelated Donors | 2 | 2017 | 44 | 0.170 |
Why?
|
Antigens, CD34 | 3 | 2017 | 158 | 0.170 |
Why?
|
Nuclear Proteins | 2 | 2000 | 721 | 0.160 |
Why?
|
Genes, Tumor Suppressor | 1 | 1999 | 159 | 0.160 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2017 | 237 | 0.150 |
Why?
|
Adolescent | 6 | 2017 | 9111 | 0.150 |
Why?
|
Comorbidity | 4 | 2018 | 941 | 0.150 |
Why?
|
HLA Antigens | 2 | 2016 | 226 | 0.150 |
Why?
|
Cells, Cultured | 8 | 2006 | 2844 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2003 | 334 | 0.140 |
Why?
|
Health Services Misuse | 1 | 2016 | 19 | 0.140 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 141 | 0.140 |
Why?
|
Leukemia | 1 | 1999 | 321 | 0.140 |
Why?
|
Azacitidine | 1 | 2017 | 139 | 0.140 |
Why?
|
Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 2 | 2006 | 6 | 0.140 |
Why?
|
Time Factors | 3 | 2011 | 5284 | 0.140 |
Why?
|
Paramyxoviridae | 1 | 2015 | 10 | 0.140 |
Why?
|
Haploidy | 1 | 2016 | 32 | 0.140 |
Why?
|
Lipopolysaccharides | 5 | 2005 | 292 | 0.130 |
Why?
|
Chromones | 3 | 2006 | 29 | 0.130 |
Why?
|
Lymphoma | 1 | 2017 | 264 | 0.130 |
Why?
|
Enzyme Activation | 5 | 2005 | 694 | 0.130 |
Why?
|
Blood Donors | 1 | 2015 | 24 | 0.130 |
Why?
|
Morpholines | 3 | 2006 | 67 | 0.130 |
Why?
|
fas Receptor | 4 | 2004 | 76 | 0.130 |
Why?
|
Community-Acquired Infections | 1 | 2015 | 64 | 0.130 |
Why?
|
Sodium Salicylate | 2 | 2006 | 4 | 0.130 |
Why?
|
Taiwan | 2 | 2011 | 23 | 0.130 |
Why?
|
Respiratory Tract Infections | 1 | 2015 | 107 | 0.130 |
Why?
|
Donor Selection | 1 | 2015 | 73 | 0.130 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 100 | 0.130 |
Why?
|
Cell Differentiation | 4 | 2008 | 1501 | 0.120 |
Why?
|
Interleukin-6 | 4 | 2004 | 260 | 0.120 |
Why?
|
Survival Rate | 2 | 2015 | 1877 | 0.120 |
Why?
|
Hematopoietic Stem Cells | 1 | 2016 | 297 | 0.120 |
Why?
|
Consensus | 1 | 2015 | 349 | 0.110 |
Why?
|
Glucocorticoids | 1 | 2015 | 358 | 0.110 |
Why?
|
Cell Line | 3 | 2011 | 2491 | 0.110 |
Why?
|
Transplantation, Haploidentical | 3 | 2017 | 27 | 0.110 |
Why?
|
Adenine Nucleotides | 1 | 2013 | 63 | 0.110 |
Why?
|
Arabinonucleosides | 1 | 2013 | 39 | 0.110 |
Why?
|
Intensive Care Units | 1 | 2016 | 381 | 0.110 |
Why?
|
Transplantation Chimera | 1 | 2013 | 81 | 0.110 |
Why?
|
Clinical Decision-Making | 1 | 2015 | 268 | 0.110 |
Why?
|
Tissue Donors | 2 | 2013 | 490 | 0.110 |
Why?
|
Apoptosis Regulatory Proteins | 3 | 2004 | 201 | 0.110 |
Why?
|
Surgery, Computer-Assisted | 1 | 2013 | 98 | 0.110 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 3 | 2000 | 35 | 0.110 |
Why?
|
Receptors, Cell Surface | 2 | 2004 | 289 | 0.100 |
Why?
|
Caspase 8 | 4 | 2005 | 34 | 0.100 |
Why?
|
Mice | 7 | 2011 | 11619 | 0.100 |
Why?
|
Hematoma, Epidural, Cranial | 1 | 2011 | 4 | 0.100 |
Why?
|
Neoplasms | 2 | 2018 | 2984 | 0.100 |
Why?
|
Hematopoiesis | 1 | 2013 | 164 | 0.100 |
Why?
|
Extravasation of Diagnostic and Therapeutic Materials | 1 | 2011 | 15 | 0.100 |
Why?
|
Miniaturization | 1 | 2011 | 14 | 0.100 |
Why?
|
Spectrophotometry | 1 | 2011 | 107 | 0.100 |
Why?
|
Magnetite Nanoparticles | 1 | 2011 | 27 | 0.100 |
Why?
|
Adult Stem Cells | 1 | 2011 | 29 | 0.100 |
Why?
|
Flow Cytometry | 2 | 2011 | 687 | 0.100 |
Why?
|
Scattering, Radiation | 1 | 2011 | 116 | 0.100 |
Why?
|
Incidence | 2 | 2015 | 1580 | 0.100 |
Why?
|
Catheters | 1 | 2011 | 76 | 0.100 |
Why?
|
Enzyme Inhibitors | 2 | 2006 | 642 | 0.100 |
Why?
|
Reactive Oxygen Species | 2 | 2011 | 483 | 0.100 |
Why?
|
Animals | 11 | 2011 | 27028 | 0.090 |
Why?
|
I-kappa B Proteins | 2 | 2000 | 54 | 0.090 |
Why?
|
Transfection | 4 | 2006 | 907 | 0.090 |
Why?
|
Hospitalization | 1 | 2016 | 864 | 0.090 |
Why?
|
Endocytosis | 1 | 2011 | 177 | 0.090 |
Why?
|
Imatinib Mesylate | 1 | 2010 | 126 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 3 | 2018 | 858 | 0.090 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2004 | 309 | 0.090 |
Why?
|
Transplantation, Autologous | 1 | 2011 | 340 | 0.090 |
Why?
|
Radiography, Interventional | 1 | 2011 | 153 | 0.090 |
Why?
|
Equipment Design | 1 | 2011 | 415 | 0.090 |
Why?
|
Intestinal Diseases | 1 | 2010 | 79 | 0.090 |
Why?
|
Illinois | 1 | 2011 | 465 | 0.090 |
Why?
|
Nanoparticles | 1 | 2011 | 162 | 0.090 |
Why?
|
Graft Rejection | 1 | 2016 | 1079 | 0.090 |
Why?
|
Tomography, Spiral Computed | 1 | 2010 | 76 | 0.090 |
Why?
|
Benzamides | 1 | 2010 | 236 | 0.090 |
Why?
|
Contrast Media | 2 | 2011 | 1084 | 0.090 |
Why?
|
Acute Disease | 1 | 2011 | 838 | 0.090 |
Why?
|
Brain Injuries | 1 | 2011 | 162 | 0.090 |
Why?
|
Radiation Dosage | 1 | 2010 | 226 | 0.080 |
Why?
|
Inflammation | 2 | 2005 | 951 | 0.080 |
Why?
|
Fas Ligand Protein | 3 | 2004 | 49 | 0.080 |
Why?
|
Vertebrobasilar Insufficiency | 1 | 2009 | 16 | 0.080 |
Why?
|
Vertebral Artery | 1 | 2009 | 23 | 0.080 |
Why?
|
Caspase 9 | 3 | 2004 | 48 | 0.080 |
Why?
|
Neutrophils | 2 | 2016 | 307 | 0.080 |
Why?
|
Membrane Potentials | 3 | 2006 | 436 | 0.080 |
Why?
|
Adenoviridae | 4 | 2003 | 347 | 0.080 |
Why?
|
Pilot Projects | 1 | 2011 | 861 | 0.080 |
Why?
|
T-Lymphocytes | 1 | 2015 | 1209 | 0.080 |
Why?
|
Prognosis | 2 | 2018 | 3729 | 0.080 |
Why?
|
Carotid Artery, Internal | 1 | 2009 | 69 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 888 | 0.080 |
Why?
|
Interleukin-1 | 2 | 2005 | 71 | 0.080 |
Why?
|
Arthritis, Experimental | 3 | 2004 | 26 | 0.080 |
Why?
|
Vascular Surgical Procedures | 1 | 2009 | 147 | 0.080 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2009 | 138 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2011 | 1939 | 0.070 |
Why?
|
Fatty Acids | 1 | 2008 | 131 | 0.070 |
Why?
|
Upper Gastrointestinal Tract | 1 | 2007 | 10 | 0.070 |
Why?
|
Injections, Intra-Arterial | 1 | 2007 | 33 | 0.070 |
Why?
|
Hemostasis | 1 | 2007 | 21 | 0.070 |
Why?
|
Promoter Regions, Genetic | 2 | 2001 | 951 | 0.070 |
Why?
|
Caspase 3 | 2 | 2004 | 160 | 0.070 |
Why?
|
Lipopolysaccharide Receptors | 1 | 2006 | 23 | 0.070 |
Why?
|
Histocompatibility Testing | 2 | 2017 | 138 | 0.070 |
Why?
|
Steroids | 1 | 2008 | 175 | 0.070 |
Why?
|
Lipid Metabolism | 1 | 2008 | 198 | 0.070 |
Why?
|
Cell Adhesion | 1 | 2008 | 425 | 0.070 |
Why?
|
Adenosine Diphosphate | 1 | 2006 | 55 | 0.070 |
Why?
|
Base Sequence | 2 | 2001 | 2333 | 0.070 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 2 | 2004 | 115 | 0.070 |
Why?
|
Data Interpretation, Statistical | 1 | 2008 | 299 | 0.070 |
Why?
|
Severity of Illness Index | 1 | 2011 | 1827 | 0.070 |
Why?
|
Necrosis | 1 | 2006 | 208 | 0.070 |
Why?
|
Mitogen-Activated Protein Kinases | 2 | 2004 | 225 | 0.070 |
Why?
|
Anticoagulants | 1 | 2009 | 420 | 0.070 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2008 | 696 | 0.070 |
Why?
|
Adenosine Triphosphate | 1 | 2006 | 314 | 0.060 |
Why?
|
Radiography | 1 | 2007 | 810 | 0.060 |
Why?
|
Transcriptional Activation | 2 | 2003 | 286 | 0.060 |
Why?
|
RNA, Small Interfering | 1 | 2006 | 555 | 0.060 |
Why?
|
Receptors, Interleukin-1 | 1 | 2004 | 11 | 0.060 |
Why?
|
Complement Membrane Attack Complex | 1 | 2004 | 21 | 0.060 |
Why?
|
Obesity | 1 | 2010 | 957 | 0.060 |
Why?
|
Complement System Proteins | 1 | 2004 | 83 | 0.060 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2003 | 90 | 0.060 |
Why?
|
Genes, bcl-2 | 1 | 2003 | 16 | 0.060 |
Why?
|
Signal Transduction | 2 | 2006 | 3331 | 0.060 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 2003 | 17 | 0.060 |
Why?
|
Genes, p53 | 1 | 2003 | 109 | 0.050 |
Why?
|
Adjuvants, Immunologic | 1 | 2004 | 167 | 0.050 |
Why?
|
Mitochondrial Proteins | 1 | 2004 | 126 | 0.050 |
Why?
|
Cyclins | 1 | 2003 | 83 | 0.050 |
Why?
|
In Vitro Techniques | 2 | 2001 | 993 | 0.050 |
Why?
|
Capsid Proteins | 1 | 2002 | 32 | 0.050 |
Why?
|
Serine | 1 | 2003 | 102 | 0.050 |
Why?
|
Glycoproteins | 1 | 2004 | 235 | 0.050 |
Why?
|
Genes, Regulator | 1 | 2002 | 65 | 0.050 |
Why?
|
Homeostasis | 2 | 2001 | 406 | 0.050 |
Why?
|
Risk Factors | 3 | 2018 | 5405 | 0.050 |
Why?
|
Transgenes | 1 | 2002 | 181 | 0.050 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2002 | 90 | 0.050 |
Why?
|
Gene Expression Profiling | 1 | 2008 | 1414 | 0.050 |
Why?
|
bcl-Associated Death Protein | 1 | 2001 | 16 | 0.050 |
Why?
|
Caspase Inhibitors | 1 | 2001 | 33 | 0.050 |
Why?
|
Antisense Elements (Genetics) | 1 | 2001 | 9 | 0.050 |
Why?
|
Serpins | 1 | 2001 | 30 | 0.050 |
Why?
|
Interleukin-8 | 1 | 2000 | 86 | 0.050 |
Why?
|
DNA Primers | 1 | 2001 | 544 | 0.050 |
Why?
|
Phosphorylation | 1 | 2003 | 1121 | 0.050 |
Why?
|
Prospective Studies | 3 | 2014 | 4247 | 0.050 |
Why?
|
Transcription Factor RelA | 1 | 2000 | 49 | 0.050 |
Why?
|
Genetic Vectors | 4 | 2003 | 442 | 0.040 |
Why?
|
Genetic Therapy | 1 | 2002 | 354 | 0.040 |
Why?
|
Up-Regulation | 2 | 2001 | 726 | 0.040 |
Why?
|
NF-kappa B p50 Subunit | 1 | 2000 | 42 | 0.040 |
Why?
|
Disease Progression | 2 | 2016 | 1479 | 0.040 |
Why?
|
Viral Proteins | 1 | 2001 | 300 | 0.040 |
Why?
|
CASP8 and FADD-Like Apoptosis Regulating Protein | 3 | 2004 | 13 | 0.040 |
Why?
|
Growth Substances | 1 | 1999 | 80 | 0.040 |
Why?
|
Preoperative Period | 1 | 2018 | 92 | 0.040 |
Why?
|
Predictive Value of Tests | 2 | 2014 | 1697 | 0.040 |
Why?
|
Sequence Alignment | 1 | 1999 | 353 | 0.040 |
Why?
|
Saccharomyces cerevisiae Proteins | 1 | 2000 | 279 | 0.040 |
Why?
|
Premedication | 1 | 2017 | 55 | 0.040 |
Why?
|
Lymphocyte Depletion | 1 | 2017 | 97 | 0.040 |
Why?
|
Immune Tolerance | 1 | 2000 | 338 | 0.040 |
Why?
|
Repressor Proteins | 1 | 2000 | 415 | 0.040 |
Why?
|
Child | 1 | 2009 | 7065 | 0.040 |
Why?
|
Cause of Death | 1 | 2018 | 270 | 0.040 |
Why?
|
Tumor Cells, Cultured | 1 | 1999 | 1049 | 0.040 |
Why?
|
Homeodomain Proteins | 1 | 2000 | 544 | 0.040 |
Why?
|
Receptor-Interacting Protein Serine-Threonine Kinases | 2 | 2006 | 5 | 0.030 |
Why?
|
Cohort Studies | 2 | 2014 | 2802 | 0.030 |
Why?
|
Protein Binding | 1 | 2000 | 1476 | 0.030 |
Why?
|
Histocompatibility | 1 | 2016 | 66 | 0.030 |
Why?
|
Multiplex Polymerase Chain Reaction | 1 | 2015 | 34 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2016 | 222 | 0.030 |
Why?
|
Complementarity Determining Regions | 1 | 2015 | 24 | 0.030 |
Why?
|
Amino Acid Sequence | 1 | 1999 | 2061 | 0.030 |
Why?
|
Terminal Care | 1 | 2016 | 136 | 0.030 |
Why?
|
Mortality | 1 | 2016 | 150 | 0.030 |
Why?
|
Allografts | 1 | 2015 | 174 | 0.030 |
Why?
|
Transplant Recipients | 1 | 2015 | 136 | 0.030 |
Why?
|
Toll-Like Receptor 4 | 2 | 2005 | 91 | 0.030 |
Why?
|
Prevalence | 1 | 2018 | 1247 | 0.030 |
Why?
|
Molecular Sequence Data | 1 | 1999 | 3028 | 0.030 |
Why?
|
Cysteine Proteinase Inhibitors | 2 | 2006 | 53 | 0.030 |
Why?
|
Immunoglobulin Isotypes | 1 | 2013 | 31 | 0.030 |
Why?
|
Pneumococcal Vaccines | 1 | 2013 | 28 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2017 | 610 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 2013 | 65 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2013 | 96 | 0.030 |
Why?
|
Fas-Associated Death Domain Protein | 2 | 2004 | 7 | 0.030 |
Why?
|
RNA, Messenger | 3 | 2004 | 1996 | 0.030 |
Why?
|
Opportunistic Infections | 1 | 2013 | 59 | 0.030 |
Why?
|
Virus Diseases | 1 | 2013 | 96 | 0.030 |
Why?
|
Rats, Inbred Lew | 2 | 2002 | 191 | 0.030 |
Why?
|
Transcription Factors | 1 | 2000 | 1622 | 0.030 |
Why?
|
Transcription Factor AP-1 | 2 | 2003 | 65 | 0.030 |
Why?
|
Glasgow Coma Scale | 1 | 2011 | 68 | 0.030 |
Why?
|
Injury Severity Score | 1 | 2011 | 111 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2011 | 122 | 0.020 |
Why?
|
Decompression, Surgical | 1 | 2011 | 85 | 0.020 |
Why?
|
Trauma Centers | 1 | 2011 | 116 | 0.020 |
Why?
|
NF-KappaB Inhibitor alpha | 2 | 2000 | 42 | 0.020 |
Why?
|
Age Factors | 1 | 2015 | 1853 | 0.020 |
Why?
|
Needs Assessment | 1 | 2011 | 156 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2013 | 384 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2015 | 990 | 0.020 |
Why?
|
Critical Care | 1 | 2011 | 373 | 0.020 |
Why?
|
Mitochondrial ADP, ATP Translocases | 1 | 2006 | 2 | 0.020 |
Why?
|
Cyclophilins | 1 | 2006 | 8 | 0.020 |
Why?
|
Amino Acid Chloromethyl Ketones | 1 | 2006 | 25 | 0.020 |
Why?
|
bcl-X Protein | 1 | 2006 | 53 | 0.020 |
Why?
|
Permeability | 1 | 2006 | 137 | 0.020 |
Why?
|
Rats | 2 | 2002 | 4022 | 0.020 |
Why?
|
Cysteine | 1 | 2006 | 136 | 0.020 |
Why?
|
Biological Transport | 1 | 2006 | 399 | 0.020 |
Why?
|
Microscopy, Electron | 1 | 2005 | 506 | 0.020 |
Why?
|
Annexin A5 | 1 | 2004 | 20 | 0.020 |
Why?
|
Cell Death | 1 | 2006 | 261 | 0.020 |
Why?
|
DNA Fragmentation | 1 | 2004 | 63 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2011 | 3650 | 0.020 |
Why?
|
Receptors, Tumor Necrosis Factor, Member 6b | 1 | 2003 | 1 | 0.010 |
Why?
|
Adenoviridae Infections | 1 | 2003 | 17 | 0.010 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2003 | 25 | 0.010 |
Why?
|
Toll-Like Receptors | 1 | 2004 | 92 | 0.010 |
Why?
|
Matrix Metalloproteinase Inhibitors | 1 | 2003 | 14 | 0.010 |
Why?
|
Matrix Metalloproteinase 3 | 1 | 2003 | 10 | 0.010 |
Why?
|
Growth Inhibitors | 1 | 2003 | 41 | 0.010 |
Why?
|
Blotting, Western | 1 | 2004 | 794 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2003 | 78 | 0.010 |
Why?
|
Retinoblastoma Protein | 1 | 2003 | 67 | 0.010 |
Why?
|
beta-Galactosidase | 1 | 2002 | 73 | 0.010 |
Why?
|
Hindlimb | 1 | 2002 | 92 | 0.010 |
Why?
|
Gene Transfer Techniques | 1 | 2002 | 152 | 0.010 |
Why?
|
In Situ Nick-End Labeling | 1 | 2001 | 122 | 0.010 |
Why?
|
Proton-Motive Force | 1 | 2000 | 1 | 0.010 |
Why?
|
Replication Protein C | 1 | 2000 | 2 | 0.010 |
Why?
|
Down-Regulation | 1 | 2003 | 513 | 0.010 |
Why?
|
Thiocarbamates | 1 | 2000 | 6 | 0.010 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2000 | 42 | 0.010 |
Why?
|
Adenoviruses, Human | 1 | 2000 | 41 | 0.010 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2000 | 39 | 0.010 |
Why?
|
Cell Cycle | 1 | 2003 | 506 | 0.010 |
Why?
|
Cytomegalovirus | 1 | 2001 | 78 | 0.010 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2000 | 137 | 0.010 |
Why?
|
Pyrrolidines | 1 | 2000 | 59 | 0.010 |
Why?
|
Plasmids | 1 | 2001 | 292 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 2001 | 322 | 0.010 |
Why?
|
Recombination, Genetic | 1 | 2002 | 440 | 0.010 |
Why?
|
Antibodies | 1 | 2001 | 353 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2003 | 1969 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2003 | 2513 | 0.010 |
Why?
|
Gene Expression | 1 | 2001 | 1299 | 0.010 |
Why?
|
Skin | 1 | 2000 | 570 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2001 | 2317 | 0.010 |
Why?
|